Release: Drug Pricing Transparency Bill Approved by Assembly Health Committee

June 27, 2017

Senate Health Leader continues to fight Big Pharma in California for some much-needed sunshine on drug costs

SACRAMENTO – Today, the Assembly Health Committee approved passage of Senate Bill 17, which provides transparency on rising drug prices in California. 

Authored by Senator Ed Hernandez, O.D. (D-West Covina) and approved by a vote of 11-0, SB 17 provides information on drug prices, a first step toward more affordable and accessible prescription drugs for Californians.

“This bill brings sunshine to one of the biggest drivers of rising health care costs. Big Pharma needs to play by the same rules as the rest of the health care industry and provide transparency to consumers. Californians deserve to know why drug prices continue to skyrocket,” said Senator Hernandez, chair of the Senate Health Committee. “I thank the members of the Assembly Health Committee who saw the value in putting patients before profits.”

SB 17 will promote transparency by requiring drug makers to give notice to purchasers before raising prices and requiring health plans to report the proportion of the premiums spent on prescription drugs. SB 17 has amassed a diverse support coalition of over 90 consumer, business, labor, local government and health care professional organizations, and is sponsored by the California Labor Federation, Health Access California, and UNITE HERE!.

SB 17 now heads to the Assembly Appropriations Committee.


The Sacramento Bee – Opinion: The difference between life and death for diabetics

The San Francisco Chronicle – Opinion: Require drug makers to report when they raise prices

The Mercury News – Editorial: Bring transparency to prescription drug pricing

The Los Angeles Times – Editorial: Are pharmaceutical companies gouging taxpayers? Lawmakers need to find out

La Opinión: Proponen ley para impedir cambios drásticos en costos de medicamentos